Lotus Reported Unaudited April Consolidated Revenues of NT$2,017 million, Doubling over year on year
May 10th , 2023, Taipei
Lotus Pharmaceutical Co., Ltd ("Lotus" or "the Company," Taiwan TWSE ticker: 1795) has released its monthly revenue report for April 2023, with unaudited consolidated revenues of NT$2,017,216 thousand. This marks a significant growth of 41.0% compared to the previous month, and an impressive doubling over the same period last year.
The revenue growth was primarily driven by several factors, including Lenalidomide sales in markets outside Asia, and the generic version of Xtandi®, Enzalutamide, delivered increased revenue resulted from the market expansion in Latin America.
Furthermore, the Company's Asian businesses showed sustainable growth, while revenue in Taiwan saw a remarkable 73% growth year-on-year, driven by the newly acquired brands Cialis® and Alimta®, which significantly boosted the performance of Taiwan's drug store channel and Oncology businesses. The Company's other products in the key therapeutic areas, such as osteoporosis, Parkinson's, cough and cold, also delivered solid results.
The Company's cumulative unaudited consolidated revenue for the first four months of 2023 also showed a significant increase, reaching NT$6,541,075 thousand, representing a growth of 57.2% over the same period last year.
Lotus Pharmaceutical continues to pursue its expansion strategy in the Asia and export markets, while also transforming into a hybrid pharma player by expanding its generic business with a synergetic portfolio of Brands, 505(b)(2)s, and NCEs. The Company remains committed to prioritizing production efficiency and customer service to become an end-to-end global platform.
Susan Liao, IR/PR Director